AR063628A1 - Compuestos de piridinona utiles para el tratamiento de cancer - Google Patents
Compuestos de piridinona utiles para el tratamiento de cancerInfo
- Publication number
- AR063628A1 AR063628A1 ARP070104987A ARP070104987A AR063628A1 AR 063628 A1 AR063628 A1 AR 063628A1 AR P070104987 A ARP070104987 A AR P070104987A AR P070104987 A ARP070104987 A AR P070104987A AR 063628 A1 AR063628 A1 AR 063628A1
- Authority
- AR
- Argentina
- Prior art keywords
- useful
- piridinone
- compounds
- cancer treatment
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Compuestos de piridinona útiles para modular la cinasa Met, que tiene la siguiente estructura (1) y además composiciones farmacéuticas que comprenden el compuesto, y métodos para tratar enfermedades proliferativas, tales como cáncer por la administración de este compuesto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85754006P | 2006-11-08 | 2006-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063628A1 true AR063628A1 (es) | 2009-02-04 |
Family
ID=39048786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104987A Pending AR063628A1 (es) | 2006-11-08 | 2007-11-08 | Compuestos de piridinona utiles para el tratamiento de cancer |
Country Status (21)
Country | Link |
---|---|
US (2) | US7851489B2 (es) |
EP (1) | EP2089364B1 (es) |
JP (1) | JP5276005B2 (es) |
KR (1) | KR101390076B1 (es) |
CN (1) | CN101535264B (es) |
AR (1) | AR063628A1 (es) |
AU (1) | AU2007317296B2 (es) |
CA (1) | CA2669266C (es) |
CL (1) | CL2007003226A1 (es) |
DK (1) | DK2089364T3 (es) |
ES (1) | ES2424851T3 (es) |
HK (1) | HK1131608A1 (es) |
HR (1) | HRP20130626T1 (es) |
MX (1) | MX2009004699A (es) |
NO (1) | NO342395B1 (es) |
PE (1) | PE20081490A1 (es) |
PL (1) | PL2089364T3 (es) |
PT (1) | PT2089364E (es) |
SI (1) | SI2089364T1 (es) |
TW (1) | TWI409259B (es) |
WO (1) | WO2008058229A1 (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8558000B2 (en) | 2008-01-23 | 2013-10-15 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
EP2563773A1 (en) | 2010-04-29 | 2013-03-06 | Deciphera Pharmaceuticals, LLC | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
PL2563763T3 (pl) * | 2010-04-30 | 2015-06-30 | Bristol Myers Squibb Co | Kompozycje farmaceutyczne zawierające N-(4-(2-amino-3-chloropirydyn-4-yloksy)-3-fluorofenylo)-4-etoksy-1-(4-fluorofenylo)-2-okso- 1,2-dihydropirydyno-3-karboksyamid |
CN102241625B (zh) * | 2010-05-13 | 2014-10-29 | 中南大学 | 1-(取代芳基)-5-((取代芳胺基)甲基)吡啶-2(1h)酮化合物、制备方法及其用途 |
CN102070518B (zh) * | 2011-01-24 | 2012-05-02 | 江苏先声药物研究有限公司 | 取代吡啶及氮杂吲哚衍生物的合成 |
SG10201801668WA (en) | 2011-06-10 | 2018-03-28 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
CN104302292A (zh) * | 2011-11-22 | 2015-01-21 | 德西费拉制药有限责任公司 | 表现出抗癌和抗增殖活性的吡啶酮酰胺以及类似物 |
US8975282B2 (en) | 2012-07-28 | 2015-03-10 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
ES2634414T3 (es) | 2012-07-28 | 2017-09-27 | Calitor Sciences, Llc | Compuestos de pirazolona sustituida y métodos de uso |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
SG10202004618TA (en) | 2015-11-19 | 2020-06-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
US20170174679A1 (en) | 2015-12-22 | 2017-06-22 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
MD3472167T2 (ro) | 2016-06-20 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
ES2930092T3 (es) * | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
JP7063902B2 (ja) * | 2016-12-19 | 2022-05-09 | ノバルティス アーゲー | 新たなピコリン酸誘導体及び中間体としてのその使用 |
ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
MX2019007416A (es) | 2016-12-22 | 2019-12-11 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores. |
WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
WO2018136010A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
TW201834649A (zh) | 2017-03-02 | 2018-10-01 | 新加坡商亞獅康私人有限公司 | 癌症療法 |
CN108623568B (zh) * | 2017-03-21 | 2022-04-19 | 南京汇诚制药有限公司 | 9,10二氢菲类丙型肝炎病毒抑制剂的盐型及其制备 |
WO2018222135A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
WO2018222134A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
WO2019083456A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER FOR NORMALIZING ANGIOGENESIS IN A CANCER MASS |
WO2019083455A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS PRESENTING HER1, HER2 AND / OR HER3-ACTIVATED HERC-RECEPTOR CANCER CELLS |
WO2019083457A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS MUTATION OF THE BETA-CATENIN PATHWAY |
WO2019083458A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR THE TREATMENT OF CANCER TO REDUCE HYPOXIA |
JP7377798B2 (ja) * | 2017-11-24 | 2023-11-10 | 南京明徳新薬研発有限公司 | c-MET/AXL阻害剤としてのウラシル系化合物 |
CN111295386B (zh) | 2018-03-08 | 2022-09-06 | 伟迈可生物有限公司 | 噻吩并吡啶衍生物及含有该衍生物的药物组合物 |
HRP20230306T1 (hr) | 2018-05-11 | 2023-05-12 | Incyte Corporation | Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori |
CN112969699A (zh) | 2018-10-09 | 2021-06-15 | 亚狮康私人有限公司 | 瓦利替尼的丙二酸盐 |
US20210379077A1 (en) * | 2018-10-19 | 2021-12-09 | The University Of British Columbia | Topoisomerase ii catalytic inhibitor compound therapeutics for cancer treatment, methods and uses |
WO2020150307A1 (en) * | 2019-01-15 | 2020-07-23 | The Translational Genomics Research Institute | Phosphonate conjugates and uses thereof |
EP4011885A4 (en) | 2019-08-02 | 2023-01-18 | Wellmarker Bio Co., Ltd. | OXO-PYRIDINE FUSION RING DERIVATIVES AND THIS COMPREHENSIVE PHARMACEUTICAL COMPOSITION |
US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
JP2022554042A (ja) | 2019-09-06 | 2022-12-28 | ウェルマーカー・バイオ・カンパニー・リミテッド | バイオマーカー型治療用組成物 |
WO2021096849A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
WO2021158071A1 (ko) | 2020-02-06 | 2021-08-12 | 웰마커바이오 주식회사 | Kras 돌연변이와 관련된 암의 예방 또는 치료용 약학 조성물 |
EP4115887A1 (en) | 2020-03-03 | 2023-01-11 | Wellmarker Bio Co., Ltd. | Pharmaceutical composition for prevention or treatment of cancer in which kras mutation and activated ron are present |
EP4154892A4 (en) | 2020-05-18 | 2023-12-06 | Wellmarker Bio Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SMALL CELL LUNG CANCER ASSOCIATED WITH RON MUTANTS AND METHOD USING SAME |
EP4154890A4 (en) | 2020-05-18 | 2023-12-06 | Wellmarker Bio Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF PANCREATIC CANCER ASSOCIATED WITH RON MUTATION AND METHOD USING SAME |
WO2021235812A1 (ko) | 2020-05-18 | 2021-11-25 | 웰마커바이오 주식회사 | Ron 돌연변이와 관련된 비소세포 폐암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법 |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
CN116745279A (zh) * | 2021-02-02 | 2023-09-12 | 株式会社Lg化学 | 作为蛋白激酶抑制剂的新型化合物 |
CN117355533A (zh) * | 2021-06-22 | 2024-01-05 | 株式会社Lg化学 | 作为蛋白激酶抑制剂的新型化合物 |
US20230257364A1 (en) * | 2022-02-16 | 2023-08-17 | Cmg Pharmaceutical Co., Ltd. | Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0430885A3 (en) | 1989-12-01 | 1991-11-06 | Ciba-Geigy Ag | Anthelmintical compounds |
US6143764A (en) | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
JP2002518368A (ja) | 1998-06-17 | 2002-06-25 | デュポン ファーマシューティカルズ カンパニー | メタロプロテイナーゼ阻害剤としての環式ヒドロキサム酸類 |
US6521622B1 (en) | 1999-07-20 | 2003-02-18 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
US6355660B1 (en) | 1999-07-20 | 2002-03-12 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
CZ20021009A3 (cs) | 1999-09-21 | 2002-06-12 | Astrazeneca Ab | Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv |
FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
SE0102384D0 (sv) | 2001-07-03 | 2001-07-03 | Pharmacia Ab | New compounds |
CA2468716A1 (en) | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
JP4829506B2 (ja) | 2004-02-17 | 2011-12-07 | 石原産業株式会社 | チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤 |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
EP1751136B1 (en) | 2004-05-07 | 2014-07-02 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
US7732613B2 (en) | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7880004B2 (en) | 2005-09-15 | 2011-02-01 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
-
2007
- 2007-11-08 MX MX2009004699A patent/MX2009004699A/es active IP Right Grant
- 2007-11-08 WO PCT/US2007/084047 patent/WO2008058229A1/en active Application Filing
- 2007-11-08 ES ES07844974T patent/ES2424851T3/es active Active
- 2007-11-08 CN CN2007800414202A patent/CN101535264B/zh active Active
- 2007-11-08 EP EP07844974.1A patent/EP2089364B1/en active Active
- 2007-11-08 PE PE2007001538A patent/PE20081490A1/es active IP Right Grant
- 2007-11-08 CA CA2669266A patent/CA2669266C/en active Active
- 2007-11-08 AR ARP070104987A patent/AR063628A1/es active Pending
- 2007-11-08 JP JP2009536476A patent/JP5276005B2/ja active Active
- 2007-11-08 PL PL07844974T patent/PL2089364T3/pl unknown
- 2007-11-08 SI SI200731303T patent/SI2089364T1/sl unknown
- 2007-11-08 CL CL200703226A patent/CL2007003226A1/es unknown
- 2007-11-08 TW TW096142253A patent/TWI409259B/zh active
- 2007-11-08 AU AU2007317296A patent/AU2007317296B2/en active Active
- 2007-11-08 US US11/936,984 patent/US7851489B2/en active Active
- 2007-11-08 DK DK07844974.1T patent/DK2089364T3/da active
- 2007-11-08 PT PT78449741T patent/PT2089364E/pt unknown
- 2007-11-08 KR KR1020097009449A patent/KR101390076B1/ko active IP Right Grant
-
2009
- 2009-04-22 NO NO20091605A patent/NO342395B1/no unknown
- 2009-11-02 HK HK09110170.2A patent/HK1131608A1/xx unknown
-
2010
- 2010-11-08 US US12/941,419 patent/US8536200B2/en active Active
-
2013
- 2013-07-03 HR HRP20130626TT patent/HRP20130626T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CN101535264B (zh) | 2012-11-28 |
KR20090096423A (ko) | 2009-09-10 |
HK1131608A1 (en) | 2010-01-29 |
PE20081490A1 (es) | 2008-10-30 |
ES2424851T3 (es) | 2013-10-09 |
TWI409259B (zh) | 2013-09-21 |
TW200829564A (en) | 2008-07-16 |
WO2008058229A1 (en) | 2008-05-15 |
EP2089364A1 (en) | 2009-08-19 |
AU2007317296A1 (en) | 2008-05-15 |
JP5276005B2 (ja) | 2013-08-28 |
JP2010509362A (ja) | 2010-03-25 |
US8536200B2 (en) | 2013-09-17 |
CN101535264A (zh) | 2009-09-16 |
PT2089364E (pt) | 2013-08-26 |
CL2007003226A1 (es) | 2008-02-08 |
NO342395B1 (no) | 2018-05-14 |
CA2669266A1 (en) | 2008-05-15 |
US7851489B2 (en) | 2010-12-14 |
HRP20130626T1 (en) | 2013-08-31 |
NO20091605L (no) | 2009-05-27 |
DK2089364T3 (da) | 2013-09-02 |
EP2089364B1 (en) | 2013-06-12 |
PL2089364T3 (pl) | 2013-11-29 |
CA2669266C (en) | 2014-04-29 |
US20110052583A1 (en) | 2011-03-03 |
KR101390076B1 (ko) | 2014-04-29 |
MX2009004699A (es) | 2009-05-15 |
SI2089364T1 (sl) | 2013-10-30 |
US20080114033A1 (en) | 2008-05-15 |
AU2007317296B2 (en) | 2012-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR063628A1 (es) | Compuestos de piridinona utiles para el tratamiento de cancer | |
BR112012000968A8 (pt) | Composto, composição e método para inibir uma fosfatidil inositol-3 cinase. | |
BRPI0720551A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
BR112014029851A2 (pt) | composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, método para tratamento de um tumor, e, agente para tratamento de um tumor | |
DOP2010000013A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
CL2011003082A1 (es) | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa. | |
EA201001847A1 (ru) | Соединения и композиции, применяемые для лечения малярии | |
CR11201A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
CL2008002243A1 (es) | Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2008000946A1 (es) | Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun | |
UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
ECSP099445A (es) | Quinazolinas para la inhibición de pdk1 | |
EA201170772A1 (ru) | Органические соединения | |
UA95644C2 (ru) | Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний | |
BR112013028430A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto | |
CR20110092A (es) | Nuevos compuestos utiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
MX2009007944A (es) | Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium. | |
CR20110103A (es) | Heteroarilos sustituidos | |
CY1111203T1 (el) | 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r | |
UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
TW200738659A (en) | Novel compounds | |
BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos |